Cyclotide Peptide Conjugates for Blood-Brain Barrier Transcytosis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The blood-brain barrier (BBB) restricts the access of pharmacological agents to the central nervous system, making it difficult to deliver therapeutic and diagnostic agents effectively across this barrier.
Innovation Solution
Modified cyclotides comprising peptides that bind to specific receptors involved in blood-brain barrier transcytosis, such as transferrin receptor, insulin-like growth factor type 1 receptor, Erb-B2 Receptor Tyrosine Kinase 3, leptin receptor, and low-density lipoprotein receptor-related protein 1, are used to facilitate the transport of therapeutic and diagnostic agents across the BBB.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Object-affected harmful factors
If the blood-brain barrier performs neuroprotective function by tightly controlling access to the brain, then brain protection against toxic substances is improved, but access of pharmacological agents to cerebral tissues is impeded
Solution Approach 1:
The patent uses transferrin receptor-mediated transcytosis as an intermediary mechanism to transport therapeutic agents across the BBB. The cyclotide conjugates act as mediators that bind to transferrin receptors on the BBB endothelial cells, facilitating the transfer of cargo molecules from the blood side to the brain side without compromising the barrier's protective function.
Solution Approach 2:
The patent modifies the cyclotide structure by conjugating it to therapeutic agents and potentially altering its molecular weight, charge, and hydrophobicity parameters. These parameter changes enable the cyclotide to exploit the transferrin receptor pathway while maintaining stability and efficacy for BBB traversal.
2Reliability
If brain capillaries possess few fenestrae and few endocytic vesicles compared to other organs, then BBB integrity is maintained, but transit of large hydrophilic molecules is restricted
Solution Approach 1:
The patent employs the transferrin receptor as a mediator to bypass the limitation of few fenestrae and endocytic vesicles. By conjugating therapeutic agents to cyclotides that bind transferrin receptors, the system utilizes receptor-mediated endocytosis and transcytosis pathways that are more abundant and efficient than passive diffusion through fenestrae.
Solution Approach 2:
The patent creates composite structures by conjugating cyclotides to therapeutic agents. This composite approach combines the BBB-traversing capability of cyclotides with the therapeutic functionality of the attached agents, enabling efficient delivery while maintaining BBB integrity.
3Productivity
If modified cyclotides are designed to bind to transferrin receptor for BBB transcytosis, then delivery efficiency to CNS is improved, but molecular complexity increases
Solution Approach 1:
The patent segments the delivery system into distinct functional modules: the cyclotide portion that binds to the transferrin receptor, the linker that provides stability and flexibility, and the therapeutic cargo. This segmentation allows each component to be optimized independently while working together as an integrated delivery system.
Solution Approach 2:
The cyclotide acts as an intermediary molecule that bridges the therapeutic agent and the transferrin receptor. This intermediary approach simplifies the overall design by using a well-characterized natural peptide (cyclotide) with known receptor binding properties, rather than designing entirely de novo complex molecules.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The modified cyclotides enhance the delivery of therapeutic and diagnostic agents to the central nervous system by improving transcytosis efficiency and stability, allowing for effective treatment and diagnosis of neurological conditions.
Implementation Method 1
a peptide that binds to a blood-brain barrier trancytosis receptor (BBB-R) selected from the group consisting of transferrin receptor (TrfR), insulin-like growth factor type 1 receptor (IGFR), Erb-B2 Receptor Tyrosine Kinase 3 (ErbB3), leptin receptor (ObR), low-density lipoprotein receptor-related protein 1 (LRP-1), and receptor for advanced glycation-end products (RAGE)
Data Source
AI summary
Provided are peptides able to bind a receptor that mediates receptor-mediating transcytosis (RMT) across the blood-brain barrier (BBB), as well as binding molecules that incorporate the peptides. Also provided are conjugates, including fusion proteins, composed of the peptides or binding molecules and a therapeutic or diagnostic agent. In some embodiments, the conjugates are able to pass through the blood-brain barrier after being parenterally administered to allow for function of the therapeutic or diagnostic agent in the central nervous system. Also provided are methods of making and using the provided peptides and molecules.